GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » Insider Ownership

Alliance Pharma (LSE:APH) Insider Ownership : 10.32 % (As of May. 16, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Alliance Pharma's insider ownership is 10.32%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Alliance Pharma's Institutional Ownership is 25.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Alliance Pharma's Float Percentage Of Total Shares Outstanding is 0.00%.


Alliance Pharma Insider Ownership Historical Data

The historical data trend for Alliance Pharma's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma Insider Ownership Chart

Alliance Pharma Historical Data

The historical data trend for Alliance Pharma can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Insider Ownership 10.32 10.32 10.32 10.32 10.32 10.32 10.32 10.32 10.32 10.32

Alliance Pharma Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Alliance Pharma (LSE:APH) Business Description

Traded in Other Exchanges
Address
Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB
Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).